跳至主要内容
临床试验/NCT00289731
NCT00289731已完成4 期

Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals' Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines

GlaxoSmithKline10 个研究点 分布在 3 个国家目标入组 596 人开始时间: 2003年11月24日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
596
试验地点
10
主要终点
Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value

研究概览

简要总结

The focus of this study is to evaluate how risk factors like age, gender, body mass index, smoking, alcohol consumption, etc. can influence immune response when subjects are vaccinated with GSK Biologicals' combined hepatitis A/hepatitis B vaccine or monovalent hepatitis A and B vaccines (from GSK Biologicals' or different manufacturers). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

详细描述

The study will also evaluate the persistence of hepatitis A and hepatitis B antibodies at months 12, 24 and 36 after the first dose of primary vaccination course.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
41 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value

时间窗: At Month 7

Seropositivity for anti-HAV antibodies was defined as anti-HAV antibody concentration ≥ 15mIU/mL; seropositivity for anti-HBs antibodies was defined as anti-HBs antibody concentration ≥ 3.3 mIU/mL.

Number of Seroprotected Subjects Against Hepatitis B Surface (HBs) Antigen

时间窗: At Month 7

A seroprotected subject was defined as a vaccinated subject with a serum anti-HBs antibody concentration equal to or above (≥) 10 mIU/mL.

Antibody Concentrations for Anti-hepatitis A Virus (Anti-HAV) and Anti-hepatitis B Surface (Anti-HBs) Antigens

时间窗: At Month 7 after Twinrix vaccination

Anti-HAV and anti-HBs antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in milli International Units per milliliter (mIU/mL). The reference seropositivity cut-off values for anti-HAV and anti-HBs antibodies were equal to or above (≥) 15 mIU/mL and ≥ 3.3 mIU/mL, respectively.

次要结局

  • Anti-HAV and Anti-HBs Antibody Concentrations(At Month 12 (M12), Month 24 (M24) and Month 36 (M36))
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value, by Gender(At Month 7)
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value, by Age(At Month 7)
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value, by Body Mass Index (BMI)(At Month 7)
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value, by Smoking Status(At Month 7)
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value, by Alcohol Consumption(At Month 7)
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value, by Concomitant Medication(At Month 7)
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value, by Medical Condition(At Month 7)
  • Number of Seroprotected Subjects Against HBs Antigen, by Gender(At Month 7)
  • Number of Seroprotected Subjects Against HBs Antigen, by Age(At Month 7)
  • Number of Seroprotected Subjects Against HBs Antigen, by BMI(At Month 7)
  • Number of Seroprotected Subjects Against HBs Antigen, by Smoking Status(At Month 7)
  • Anti-HAV and Anti-HBs Antibody Concentrations, by Concomitant Medication(At Month 7)
  • Anti-HAV and Anti-HBs Antibody Concentrations, by Medical Condition(At Month 7)
  • Number of Subjects With Anti-HAV and Anti-HBs Antibody Concentrations Above the Cut-off Value(At Month 12 (M12), Month 24 (M24) and Month 36 (M36))
  • Number of Seroprotected Subjects Against Hepatitis B Surface (HBs) Antigen(At Month 12 (M12), Month 24 (M24) and Month 36 (M36))
  • Number of Subjects With Serious Adverse Events (SAEs)(From Day 0 up to Month 7)
  • Number of Seroprotected Subjects Against HBs Antigen, by Alcohol Consumption(At Month 7)
  • Number of Seroprotected Subjects Against HBs Antigen, by Concomitant Medication(At Month 7)
  • Number of Seroprotected Subjects Against HBs Antigen, by Medical Condition(At Month 7)
  • Anti-HAV and Anti-HBs Antibody Concentrations, by Gender(At Month 7)
  • Anti-HAV and Anti-HBs Antibody Concentrations, by Age(At Month 7)
  • Anti-HAV and Anti-HBs Antibody Concentrations, by BMI(At Month 7)
  • Anti-HAV and Anti-HBs Antibody Concentrations, by Smoking Status(At Month 7)
  • Anti-HAV and Anti-HBs Antibody Concentrations, by Alcohol Consumption(At Month 7)
  • Number of Subjects With SAEs(At Month 12 (M12), Month 24 (M24) and Month 36 (M36))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验

Effect of Risk Factors Likely to Influence Immuno of... | 临床试验